Declining stocks outnumbered rising ones by 727 to 595 and 38 ended unchanged on the Shanghai Stock Exchange. The CBOE China Etf Volatility, which measures the implied volatility of Shanghai Composite options, was up 0.09% to 22.08. In commodities trading ... ( read original story ...)
China’s falling bond yields steal the spotlight from stock-market bulls
While declines in equity prices push up the earnings yield on the nation’s US$7.4 trillion stock market, gains in the 10-year government bond have driven down its yield since November. The yield spread between the benchmark Shanghai Composite Index and ... ( read original story ...)
Abu Dhabi Global Market to establish Belt Road Exchange with Shanghai Stock Exchange
ABU Dhabi Global Market, the international financial centre of Abu Dhabi, UAE (ADGM) and Shanghai Stock Exchange (SSE) have signed a memorandum of understanding (MoU) to establish an international “Belt and Road Exchange”. The MoU was signed on April 23. ( read original story ...)
China Updates Financial Court System as Cases Grow More Complex
BEIJING—China is setting up a special court in Shanghai to deal with the complex financial cases that are rising apace with the deepening of the country’s financial system. The Shanghai Financial Court is expected to start operations by the end of ... ( read original story ...)
All the things China market analysts got wrong in 2018
A pedestrian walks past the Shanghai Stock Exchange building in China ... who helps manage $3.7bn as BNP Paribas Asset Management’s deputy head of emerging-market debt in London. “Clearly, none of these materialised.” There have been tentative ... ( read original story ...)
Two China biotechs drop US IPO plans for $800 million Hong Kong floats
Innovent declined to comment on its IPO plans. The two companies chose Hong Kong because ... Innovent and Ascentage will be following Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun International, diabetes-focused drug developer Hua Medicine ... ( read original story ...)
Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources
Innovent declined to comment on its IPO plans. The two companies chose Hong Kong because ... Innovent and Ascentage will be following Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun International, diabetes-focused drug developer Hua Medicine ... ( read original story ...)